Spark Therapeutics Inc. will be the first drug maker to bring a gene therapy to the US market – Luxturna (voretigene neparvovec-rzyl) for a rare inherited blindness – and now the company is pioneering new reimbursement approaches to pay for what will be an expensive one-time treatment.
The First US Gene Therapy Maker Innovates On Pricing And Reimbursement
Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.
More from Sensory
• By
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
• By
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
• By
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
• By
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.
More from Therapy Areas
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.